COVID-19疫苗抗感染效果轨迹的估计
UNLABELLED: This large-scale cohort study conducted in Hong Kong examined the time-varying protective effects of various COVID-19 vaccines and dosing regimens against the Omicron BA.1/BA.2 variants.…
要点
- 单剂最大保护效果:CoronaVac为0.120,Comirnaty为0.171。
- 第二剂和第三剂峰值保护效果分别为0.348和0.522。
- 四剂方案最大保护效果CoronaVac为0.548、Comirnaty为0.784,末剂后6个月分别稳定在0.487和0.714。
核心结论
- 理解疫苗保护随时间减弱对优化疫苗接种策略、加强针安排和公共卫生政策至关重要,持续监测疫苗效果在病毒演化背景下仍然关键。
研究设计与样本
- 使用四参数药代动力学/药效学模型估计疫苗效果随时间变化的轨迹。
主要发现
- 单剂最大保护效果CoronaVac为0.120,Comirnaty为0.171。
- 第二剂和第三剂峰值保护效果分别为0.348和0.522。
- 四剂方案最大保护效果CoronaVac为0.548、Comirnaty为0.784,末剂后6个月分别稳定在0.487和0.714。
- 疫苗效果呈先升后降模式,约在接种后1-2个月达峰。
临床怎么用
- 原文结论指出,理解疫苗保护随时间减弱对优化疫苗接种策略、加强针安排和公共卫生政策至关重要;持续监测疫苗效果在病毒演化背景下仍然关键。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This large-scale cohort study conducted in Hong Kong examined the time-varying protective effects of various COVID-19 vaccines and dosing regimens against the Omicron BA.1/BA.2 variants. An innovative pharmacokinetic/pharmacodynamic model was employed to estimate the trajectory of vaccine effectiveness over time. Results indicated that the maximum protection for a single dose reached 0.120 for CoronaVac and 0.171 for Comirnaty. The peak protective effectiveness for the second and third doses were observed at 0.348 and 0.522, respectively. In a 4-dose regimen, CoronaVac demonstrated a maximum protective effectiveness of 0.548, stabilizing at 0.487, while Comirnaty achieved a maximum effectiveness of 0.784, stabilizing at 0.714 six months after the administration of the last dose. The vaccine effectiveness exhibited a rising and then declining pattern, peaking approximately 1-2 months post-vaccination. Understanding waning immunity is crucial for optimizing vaccination strategies and policies as viral evolution continues. This real-world study captured changing dynamics that may differ from clinical trials with limited follow-up, providing essential evidence to guide the optimization of vaccination efforts. Ongoing monitoring of vaccine effectiveness remains critical as the viral landscape evolves. OBJECTIVES: This study aims to investigate the time-varying protective effects of various COVID-19 vaccines and dosing regimens against infections caused by the Omicron BA.1/BA.2 in Hong Kong. METHODS: This territory-wide cohort study from Hong Kong combined vaccination records, confirmed COVID-19 cases, and census data from January 2022 to May 2022 to comprehensively analyze the time-varying protective effects of different COVID-19 vaccines and dosing regimens against Omicron BA.1 and BA.2 infections. A 4-parameter pharmacokinetic/pharmacodynamic model was used to estimate the trajectory of vaccine effectiveness over time. RESULTS: Among 6.2 million adults, the maximum protective effectiveness for a single vaccine dose reached 0.120 for CoronaVac and 0.171 for Comirnaty. For the second and third doses, peak effectiveness were observed at 0.348 for CoronaVac and 0.522 for Comirnaty. Notably, a 4-dose regimen resulted in maximum protections of 0.548 for CoronaVac and 0.785 for Comirnaty, which stabilized at 0.487 and 0.714, respectively, six months following the last doses. The vaccine effectiveness exhibited a rising then declining pattern, peaking around 1-2 months post-vaccination, underscoring the importance of ongoing vaccination strategies. CONCLUSIONS: Understanding the waning of vaccine protection over time is critical for informing optimal vaccination strategies, booster schedules, and public health policies. This real-world study can capture changing dynamics that may differ from clinical trials which have more limited follow-up periods, and can provide crucial evidence to guide optimization of vaccination strategies. Ongoing monitoring of vaccine effectiveness remains crucial as the viral evolution continues.
引用
- Jiang J, Lam KF, Lau EHY, et al. Estimation of trajectory of COVID-19 vaccines effectiveness against infection. Vaccine. 2025. PMID: 40158307. doi:10.1016/j.vaccine.2025.127067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。